Secondary Data and Hybrid Studies
In a landscape where sophisticated payers and national entities require different kinds of evidence, the value of real-world pragmatic research has expanded dramatically as a tool to inform and guide the explanatory, pre-approval randomized clinical trials and to further assess product value and risk-benefit.
Our world today and our world in 2020, requires us to change the way that we work in order to understand the unique value of a therapy well before filing, then to demonstrate this value and communicate it to a broad group of stakeholders.
PAREXEL can further advance the clinical research process by combining research with real-world data via hybrid studies. These hybrid studies using secondary data will help clients more effectively and efficiently develop and evaluate drugs, ultimately helping reduce the cost of drug development and helping improve patient care.
- Integration of traditional prospective data, EDC-based primary research with data from EHRs, medical claims, or other secondary data sources.
- Cost-effective data that can demonstrate a product’s effectiveness and value.
- Evidence to satisfy payers’ and providers’ requirement for real-world data proving product value in clinical practice.
- Reduced data-collection burden for sites, improving satisfaction.
Site-based research that leverages Electronic Health Records (EHR) and claims data can provide pharmaceutical companies with more cost effective tools to generate the real-world evidence that translates the value of new products to patients and providers. In partnership with Optum Life Sciences, PAREXEL can deliver essential real-world evidence more efficiently and effectively across a broader range of situations than has been done previously in the industry.